5,846 Shares in Ventas, Inc. $VTR Purchased by USA Financial Formulas

USA Financial Formulas purchased a new stake in Ventas, Inc. (NYSE:VTR) in the first quarter, Holdings Channel.com reports. The firm purchased 5,846 shares of the real estate investment trust’s stock, valued at approximately $478,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Dynamic Wealth Strategies LLC acquired a new stake in shares of Ventas during the first quarter worth approximately $25,000. Wiser Advisor Group LLC acquired a new stake in Ventas in the third quarter valued at $27,000. IFC & Insurance Marketing Inc. acquired a new stake in Ventas in the fourth quarter valued at $30,000. Elyxium Wealth LLC bought a new position in Ventas during the 4th quarter valued at $33,000. Finally, Reflection Asset Management bought a new position in Ventas during the 4th quarter valued at $34,000. 94.18% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Michael J. Embler purchased 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were acquired at an average price of $78.81 per share, with a total value of $197,025.00. Following the acquisition, the director owned 19,202 shares in the company, valued at approximately $1,513,309.62. This trade represents a 14.97% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.53% of the company’s stock.

Ventas Stock Performance

Shares of VTR stock opened at $91.48 on Friday. The company has a quick ratio of 0.44, a current ratio of 0.44 and a debt-to-equity ratio of 0.86. The business has a 50 day moving average of $90.45 and a two-hundred day moving average of $86.54. Ventas, Inc. has a 52 week low of $66.38 and a 52 week high of $101.60. The company has a market cap of $46.92 billion, a P/E ratio of 169.40, a PEG ratio of 2.11 and a beta of 0.69.

Wall Street Analysts Forecast Growth

VTR has been the subject of several research analyst reports. Weiss Ratings raised shares of Ventas from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, July 21st. Wells Fargo & Company increased their price target on shares of Ventas from $93.00 to $96.00 and gave the stock an “overweight” rating in a research report on Monday, June 1st. JPMorgan Chase & Co. lifted their price target on Ventas from $93.00 to $94.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Cantor Fitzgerald boosted their price objective on Ventas from $97.00 to $102.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Finally, Scotiabank cut their price objective on Ventas from $95.00 to $88.00 and set a “sector perform” rating on the stock in a research note on Thursday, June 18th. Fifteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $98.00.

Ventas Profile

Ventas, Inc (NYSE: VTR) is a real estate investment trust (REIT) that specializes in healthcare-related real estate. The company acquires, owns and manages a diversified portfolio of properties serving the healthcare continuum, including senior housing communities, skilled nursing facilities, medical office buildings, life science and research centers, and other properties leased to healthcare providers and operators. Ventas generates revenue through long-term leases, property management and selective development activities focused on meeting the real estate needs of the healthcare sector.

Ventas’ business model combines property ownership with active asset management and capital markets activity.